CellaVision acquires a new technology platform

2014-06-23T15:00:00 CEST - English

This information was released for public disclosure on June 23, 2014 at 3.00 pm CET.

CellaVision, the world leading company in digital microscopy used in hematology, has acquired a technology platform which will be the foundation of a future development project. This new technology has the potential to develop into an affordable solution for the smaller hospital laboratories.

The acquisition was made from a U.S. high technology company, Clear Lake Medical Foundation, headed by Glenn Spaulding, M.D., which has expertise in digital microscopy. The purchase price payable in installments upon achievement of certain goals will amount to approximately $ 1 million.

"We are excited to acquire this break-through technology that should make it possible to expand our product portfolio, including new products for smaller laboratories presently outside our current target market. Implementation of the new platform will be done in close collaboration with Clear Lake Medical Foundation and begin promptly. We expect, however, that it will take a few years before the first product reaches the market," says Yvonne Mårtensson, CEO of CellaVision.

For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46708337782 | Email: yvonne.martensson@cellavision.com

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2013 sales were SEK 180 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.

This information was released for public disclosure on June 23, 2014 at 3.00 pm CET.

PDF version: Press release PDF

Subscribe to updates

It's possible to subscribe to CellaVision's press releases, financial information by e-mail and SMS.

Click here to register

Information request

Are you looking for some particular information about our company or our business?

Click here to get in touch


ABG Sundal Collier AB
Victor Forssell
+46 8 566 286 92

Rickard Anderkrans
+46 8 566 286 73

Ulrik Trattner
+46 8 5886 8589

Kristofer Liljeberg
+46 8 5886 87 63

Pareto Securities AB
Christian Lee
+46 84 02 52 67

Johan Unnérus
+46 8 402 52 68


Access our Student Resources

To access this resource, please provide the following information about yourself.